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Serum sclerostin is an independent predictor of
mortality in hemodialysis patients
Flávia Letícia Carvalho Gonçalves1†, Rosilene M Elias1†, Luciene M dos Reis1, Fabiana G Graciolli1,
Fernando Godinho Zampieri2, Rodrigo B Oliveira1, Vanda Jorgetti1 and Rosa MA Moysés1,3*
Abstract
Background: Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification.
However, whether high circulating Scl is also a risk factor for death is not well established. The purpose of this
study was to test whether serum Scl would be associated with mortality.
Methods: we measured serum Scl in a hemodialysis patients’ cohort, which was followed during a ten-year period.
Competing risk regression models were applied, as during the follow-up, patients were exposed to both events
kidney transplant and death.
Results: Ninety-one patients aged 42.3 ± 18.8 years (55% of male gender, 15% of diabetes) were included. During
the follow-up, 32 patients underwent kidney transplant and 26 patients died. Non-survivals presented higher FGF23,
higher Scl and lower creatinine. There was an association between all-cause mortality and higher Scl (HR = 2.2),
higher age (HR = 1.04) and presence of diabetes (HR = 2.27), by competing risk analyses. Even including potential
markers of mortality, as creatinine, FGF 23, and gender, Scl, age and diabetes remained significantly related to
higher mortality.
Conclusion: Serum Scl is an independent predictor of mortality in dialysis patients. However, whether clinical
interventions to modulate Scl would be able to improve these patients survival needs to be determined.
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Background
Chronic kidney disease-mineral and bone disorder
(CKD-MBD) is a major syndrome that develops as a
complication of CKD [1] and usually predicts outcomes
in observational studies [2,3]. However, the exact mecha-
nisms that could explain the link between CKD-MBD
and a higher mortality risk have not been completely
unveiled. Increasing our challenge, recent studies have
identified new molecules synthetized by the osteocytes,
such as fibroblast growth factor 23 (FGF 23), which
works as a powerful predictor of mortality and cardio-
vascular events in CKD [4]. In accordance to this, the
osteocytes have been recognized as major cells that
orchestrate bone remodeling through several molecular
mechanisms [5] and recent studies are trying to elucidate
the role of these cells in CKD-MBD pathophysiology [6].
The glycoprotein sclerostin (Scl) is synthetized by the
osteocytes, and inhibits the bone anabolic Wnt path-
way, which promotes bone formation [5]. It has already
been shown that serum levels of Scl are elevated in
hemodialysis patients, with an inverse correlation to
serum parathormone (PTH) and bone formation rate
[7]. In addition, we have recently described that increased
bone expression of Scl is a common and early event in
these patients [8], and probably plays a role in CKD-MBD
pathophysiology, potentially increasing bone resistance to
PTH. As a consequence, we would expect that higher Scl
would be associated with worse outcomes. Surprisingly, it
has recently shown in hemodialysis patients that high
circulating Scl levels are associated with improved survival
instead [9].
Therefore, there is still some debate on whether circu-
lating Scl could be a new CKD-MBD marker of outcome.
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In addition, the potential relationship of serum Scl with
another CKD-MBD markers, such as FGF 23, serum sol-
uble Klotho (sKlotho) or recently described Scl modula-
tors, such as inflammation, calcitonin [10] and others, have
not yet been evaluated.
Trying to address these questions, we tested whether
serum Scl would be associated with mortality in a
hemodialysis patients’ cohort, which was followed during
a ten-year period.
Methods
Study population
This study was done in a cohort of all prevalent patients
who underwent chronic hemodialysis treatment in Hos-
pital das Clinicas, Universidade de São Paulo, Brazil on
January of 2003 (N = 91). All patients were on high-flux,
high efficiency hemodialysis, blood flow of 350 ml/min,
dialysate flow of 800 ml/min, with bicarbonate buffer
and a polysulfone dialyzer. The schedule was 3.5 to
4.0 hours thrice a week. The dialysate content of calcium
was 1.75 mmol/l. Clinical and biochemical data were col-
lected and serum samples were stored for further analysis
on January 2003. This study protocol was reviewed and ap-
proved by the Institutional Research Ethics Committee
(Comissão de Ética para Análise de Projetos de Pesquisa
do HCFMUSP; CAPPesq # 235.350). Written consent was
obtained from each patient.
Demographic, clinical, and laboratory data
Data on age, sex, diabetes mellitus, history of cardiovascular
disease, and dialysis vintage were collected when the pa-
tients entered the study. Laboratory values of hemoglobin,
creatinine, albumin, ferritin, calcium, phosphate, alkaline
phosphatase [reference range (RR) = 32–122 U/L], parathy-
roid hormone (RR = 11–62 pg/ml, immunoradiometric
assay) and β2 microglobulin (RR = 1.0–1.7 μg/ml, chemilu-
minescent assay) were collected on January 2003. On the
same day, blood samples were collected and frozen serum
samples were stored for further analyses. We measured cal-
citonin (RR for men < 8.4 pg/ml; women < 5 pg/ml; immu-
nochemiluminometric assay), interleukin-6 (IL-6; ELISA
assay; RR =ND-12.5 pg/ml; R&D Systems, MN, USA).
sKlotho (ELISA assay, RR = 239 to 1266 pg/ml; IBL
America, MN, USA); FGF 23 (cterm FGF 23, ELISA assay;
RR = 55 ± 50 RU/ml; Immutopics, CA, USA), and Scl man-
ufactured by Teco (ELISA assay; reference range: 0.56 ±
0.13 ng/ml for premenopausal women; 0.69 ± 0.20 ng/ml
for postmenopausal women and 0.74 ± 0.27 ng/ml for men;
intra- and interassay coefficients of variation = 3.1 and
3.5%, respectively; Sissach, Switzerland).
Survival analyses
Data on all-cause death were obtained from local elec-
tronic and paper records. Patients were followed for
survival for up to 10 years. Patients were censored if they
underwent renal transplantation (n = 32) or ended the
study, which ever happened first. During this follow-up,
26 patients died and causes of death were collected
from medical records, defined as cardiovascular or
non-cardiovascular.
Statistical analyses
Categorical variables are presented as percentages and con-
tinuous variables as mean ± SD or median (25, 75 inter-
quartile), where appropriate. A chi-squared test was used
to evaluate differences in numbers of deaths between Scl
higher and lower than median limits. Differences between
groups were checked with ANOVA, t-test or Kruskal
Wallis and Mann Whitney depended on normal or skewed
distribution, respectively. Spearman correlation was done
between Scl and other variables. Since renal transplant-
ation was a competitor for mortality on follow-up in our
study, a competing risk regression was used. Competing
risk regression was performed using the approach sug-
gested by Fine and Gray [11-14] Variables elected for the
regression were those associated with mortality on univari-
ate analysis and those defined a priori of clinical relevance
(such as age and gender). This first model built was consid-
ered the initial model of this analysis. A second model
including Scl levels stratified in high (above mean values)
and low (bellow mean values) was also planned for graph-
ical representation. We subsequently explored the variables
included in the initial model by adding one variable at a
time to a new model and evaluated the behavior of the
Bayesian information criteria (BIC) of all models created in
this way. The model with the smallest BIC value was
defined as the final model [13]. The statistical analysis was
done using GraphPad Prism® software (GraphPad Software,
Inc., CA, USA) and R (version 3.0.3, “Warm Puppy” – www.
r-project.org) with the following packages: survival and
cmprsk. Two-tailed P value < 0.05 was considered statisti-
cally significant.
Results
Population characteristics and events
Baseline clinical and demographic characteristics of the
study population are presented in Table 1. Our patients
were relatively young and with a low percentage of dia-
betes. Despite that, serum Scl measured was elevated. We
also observed that serum FGF 23, as well as IL-6 were
higher than normal, whereas low sKlotho was found.
During the follow-up period, 32 patients were submitted
to kidney transplant, and 5 patients were transferred to
other dialysis centers. There were 26 deaths. The main
cause of death was cardiovascular (CV; 16 patients; due to
myocardial infarction, stroke and aortic aneurysms),
followed by infection (6 cases). Non-survivors were older
and more frequently had diabetes. They also had higher
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mean values of FGF 23 and Scl, and a lower mean value
for serum creatinine and sKlotho, as shown in Table 2.
When we compared those patients who died from CV
causes to survivors, we observed that they also were older
and with a high percentage of diabetes, with higher FGF
23 and Scl and lower serum creatinine and sKlotho. The
comparison of patients who died from other causes to survi-
vors revealed that they presented lower hemoglobin and cre-
atinine and higher IL-6. Finally, patients who died from CV
causes were older than those who died from other causes.
Serum Scl was higher in men than women [1.29 ng/ml
(0.71, 1.65) vs. 0.71 ng/ml (0.42, 1.02); p = 0.001]. There
was no difference in Scl levels regarding diabetes and age.
Subsequently, patients were divided according to Scl
high or low (Table 3). Patients with high Scl were on
dialysis for longer, had higher β2 microglobulin, and
higher FGF 23. There was a tendency toward to present
a higher serum calcitonin. Age, sex and diabetes were
not different. Most cardiovascular and all-cause mortal-
ity were seen in the high Scl group.
There was a relationship between Scl and calcitonin
(r = 0.224, p = 0.035), β2 microglobulin (r = 0.333,
p = 0.001), IL-6 (r = 0.251, p = 0.027), and FGF 23
(r = 0.331, p = 0.002). There was no correlation
between Scl and PTH or between Scl and age.
Age, creatinine, Scl levels, FGF23 levels, gender and
presence of diabetes were elected for competing risk
Table 1 Baseline characteristics (N = 91)
RR
Age, years 42.3 ± 18.8 -
Gender male/female 55/36 -
Dialysis vintage, months 120 (48, 168) -
Diabetes, n (%) 14 (15.4) -
Hemoglobin, g/dl 11.5 ± 1.6 13-18
Creatinine, mg/dl 11.0 ± 3.3 0.7-1.2
Albumin, g/dl 4.2 ± 0.4 3.4-4.8
Ferritin, ng/ml 523 (198, 814) 30-400
Calcium, mg/dl 9.2 ± 1.3 8.6-10.2
Phosphate, mg/dl 5.2 ± 1.9 2.7-4.5
Alkaline phosphatase, U/l 82.5 (64.7, 121.8) 32-122
Parathormone, pg/ml 169 (94, 325) 11-62
Calcitonin, pg/ml 2.8 (2.0, 5.0) M < 8.4; F < 5
β2 microglobulin, μg/ml 27 (22, 34) 1.0-1.7
IL-6, pg/ml 3.0 (1.7, 5.0) ND-12.5
sKlotho, pg/ml 40.6 (2.8, 83.6) 239-1266
FGF23, RU/ml 135.3 (125.8, 166.9) 5-105
Scl, ng/ml 0.88 (0.54, 1.55) M: 0.5-1.0; F: 0.5-0.9
RR: Reference Range; M: male; F: female; AP: Alkaline Phosphatase; PTH:
parathormone; Scl: sclerostin.
Table 2 Survivors and non-survivors
Survivors (n = 65) Non-survivors (n = 26)
All (CV +other causes) CV cause (n = 16) Other causes (n = 10)
Age, years 37.0 ± 13.6 55.4 ± 23.2a 63.0 ± 20.6a 43.3 ± 22.8c
Gender M/F 37/28 18/8 11/5 7/3
Dialysis vintage, mo 132 (48, 180) 84 (63, 105) 96 (48, 126) 72 (60,84)
Diabetes, n 5 9a 7a 2
Hemoglobin, g/dl 11.7 ± 1.5 11.0 ± 1.7 11.4 ± 1.7 10.6 ± 1.6a
Creatinine, mg/dl 11.6 ± 3.3 9.5 ± 2.9a 9.8 ± 2.6a 9.0 ± 3.5a
Albumin, g/dl 4.2 ± 0.4 4.1 ± 0.6 4.1 ± 0.7 4.1 ± 0.5
Ferritin, ng/ml 519 (175, 691) 570 (278, 902) 598 (270, 862) 570 (276,1106)
Calcium, mg/dl 9.1 ± 1.0 9.4 ± 1.3 9.5 ± 1.6 9.4 ± 0.9
Phosphate, mg/dl 5.4 ± 1.9 4.8 ± 1.8 5.3 ± 1.9 3.9 ± 1.3a
AP, U/l 82 (65, 122) 81 (68, 127) 77 (63, 107) 96 (68,158)
PTH, pg/ml 200 (97, 401) 133 (77, 229) 145 (91, 454) 132 (39,180)
Calcitonin, pg/ml 2.8 (2.0,4.9) 3.2 (2.0, 5.7) 2.0 (2.0, 4.82) 4.6 (2.0, 7.6)
β2micro, μg/ml 28 (22, 34) 25 (16, 30) 24 (19, 30) 30 (12, 45)
IL-6, pg/ml 2.8 (1.4, 4.2) 3.3 (2.3, 12.7) 3.0 (2.3, 6.9) 12.7 (2.0, 27.9)a
Klotho, pg/ml 46.8 (7.6, 82.8) 15.7 (0.1, 103.0) 8.7 (0.1, 45.1)b 114.3 (3.7, 167.7)
FGF 23, RU/ml 134 (122, 159) 147 (129, 197)a 150 (129,311)a 143 (133, 152)
Scl, ng/ml 0.76 (0.50, 1.34) 1.45 (0.83, 1.79)a 1.63 (1.20, 1.87)a 0.84 (0.45, 1.73)
M: male; F: female; AP: Alkaline Phosphatase; PTH: parathormone; β2micro: β2microglobulin; IL-6: interleucin; FGF 23: fibroblast growth factor; Scl: sclerostin;
ap < 0.05 vs.
survivors; bp = 0.052 vs. survivors; cp < 0.05 vs. CV cause.
Gonçalves et al. BMC Nephrology 2014, 15:190 Page 3 of 7
http://www.biomedcentral.com/1471-2369/15/190
regression. The outcome of interest was defined as mor-
tality, with transplantation as competitor. Results for this
initial model are shown in Table 4 (top frame). Scl levels
were positively associated with increased mortality over
the follow-up period (HR 2.18; 95% CI 1.41-3.38). When
Scl levels were categorized as high and low while keep-
ing all other variables, high Scl levels were associated
with a HR of 2.88 (95% CI 1.35-6.15). Cumulative inci-
dence function for high Scl levels for mortality is shown
in Figure 1. After the additive model exploration, the
final model (with lowest BIC values) included only, age
(HR 1.04; 95% CI 1.02-1.07), Scl levels (HR 2.20; 95% CI
1.35-3.56) and presence of diabetes (HR 2.27; 95% CI
1.14-4.54), as shown in Table 1 (bottom frame). Due to
limited sample size, dialysis vintage was modeled in a
distinct model, confirming that high Scl was still associ-
ated with mortality with an Exp (coef ) of 2.98; 95% CI
1.35-6.33. The other variables retained were also age and
diabetes.
Discussion
The major finding of the present study was that high
Scl was associated with CV mortality in prevalent dialysis
patients, independent of diabetes and age, in a competing
analysis approach.
In the last 20 years, several studies have tried to elucidate
the physiopathology of CKD-MBD and the link between
some of the components of this syndrome and the high
mortality usually seen in CKD patients [15]. Concomi-
tantly, the better understanding of the role of the Wnt
pathway and its inhibitors has shed light on osteoporosis
therapy during the last decade [16]. As a consequence, a
question that arises is whether alterations in the osteocyte
biology, here represented by disturbances in the Wnt path-
way, could also play a major role in CKD-MBD physiopa-
thology. Activation of this pathway, represented by the
Table 3 Comparison between patients with low and high Sclerostin
Variable Low Scl (< 0.88 ng/ml) N = 45 High Scl (≥ 0.88 ng/ml) N = 46 p
Calcitonin, pg/ml 2.3 (2.0, 3.4) 3.5 (2.0, 6.0) 0.082
Age, years 42 ± 18 43 ± 20 0.966
Gender M/F 24/22 31/14 0.103
Diabetes, n 7 7 0.964
Dialysis vintage, mos 84 (36, 144) 144 (75, 180) 0.049
Creatinine, mg/dl 10.7 ± 3.6 11.3 ± 3.1 0.372
AP, U/l 106.9 ± 93.2 108.8 ± 72.6 0.984
Calcium, mg/dl 9.2 ± 1.0 9.2 ± 1.2 0.707
Phosphate, mg/dl 5.3 ± 1.7 5.2 ± 2.1 0.877
Hemoglobin, g/dl 11.7 ± 1.3 11.4 ± 1.8 0.468
PTH, pg/ml 133 (92, 363) 204 (91, 297) 0.835
Albumin, g/dl 4.1 ± 0.4 4.2 ± 0.5 0.224
Ferritin, ng/ml 558 (203, 851) 510 (196, 717) 0.685
β2micro, μg/ml 25.3 ± 9.6 30.0 ± 10.4 0.016
IL-6, pg/ml 2.6 (1.6, 3.8) 3.2 (1.9, 6.7) 0.112
Klotho, pg/ml 40.5 (4.6, 83.3) 40.8 (0.1, 84.6) 0.852
FGF 23, RU/ml 134 (123, 145) 149 (127, 212) 0.007
All-Cause mortality, n 8 18 0.012
CV mortality, n 1 15 0.0001
AP: Alkaline Phosphatase; PTH: parathormone; β2micro: β2microglobulin; IL-6: interleucin; FGF 23, fibroblast growth factor; CV: cardiovascular.
Table 4 Results for competing risk regression
Initial model
Variable Exp
(coef)
95% confidence
interval
p
Age (per year) 1.03 1.00-1.06 0.012
Creatinine (per unit) 0.86 0.74-1.01 0.059
Scl (per unit) 2.18 1.41-3.38 <0.001
FGF23 (per unit) 1.00 0.99-1.00 0.400
Male sex (versus
female)
0.82 0.39-1.75 0.620
Diabetes 2.40 1.16-4.98 0.018
Final model
Variable Exp
(coef)
95% confidence
interval
p
Age (per year) 1.04 1.02-1.07 <0.001
Scl (per unit) 2.20 1.35-3.56 0.001
Diabetes 2.27 1.14-4.54 0.020
Scl, sclerostin, FGF23, fibroblast grow factor 23.
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intracellular accumulation of β-catenin and its transloca-
tion to the nucleus, is linked to an increase in bone forma-
tion. Scl, the gene product of SOST, is an inhibitor of Wnt
pathway, decreasing bone formation and also increasing re-
sorption [17]. However, the current understanding of Scl
synthesis is as yet incomplete. The list of known stimula-
tors of Scl includes calcitriol, bone morphogenic proteins,
glucocorticoids, leptin, some cytokines, calcitonin [10] and
phosphate [18], whereas mechanical loading and PTH has
been shown to inhibit Scl production [16]. As most of
CKD patients present elevated PTH, we initially would ex-
pect to find low Scl levels in this population. However,
Cejka and colleagues have demonstrated elevated Scl in
prevalent dialysis patients [7]. In this same direction, an in-
creased bone expression of Scl was found in rodents and
patients with CKD [8]. Taken together, these data gener-
ated the hypothesis that elevated Scl might partially explain
the bone resistance to PTH that is commonly seen in CKD
patients. However, it is not clear if circulating Scl reflects
only the osteocytic synthesis or could also be a biomarker
of vascular calcification, where vascular smooth muscle
cells that had undergone phenotypic transition would also
secrete this protein attempting to inhibit calcification pro-
gress [19]. In line with this theory, Brandenburg and col-
leagues recently described a positive association between
serum Scl levels and aortic valve calcification, as well as an
increased Scl expression in aortic valve tissue adjacent to
areas of calcification [20]. The recognition of Scl as a bio-
marker of bone resistance to PTH and of valvular calcifica-
tion led us to investigate whether this protein could also be
associated with adverse outcomes. Indeed, we found that
high serum Scl is associated with an increased risk of death
in our cohort, decreasing life expectancy in more than five
years in a sample of relatively young dialysis patients. This
association was independent of age, sex or presence of
diabetes mellitus, which are classically linked to higher
mortality risk, and of serum FGF 23, potential CKD-MBD
markers of mortality.
We are aware that Kaplan-Meier analysis is the most
popular method used to estimate time-to-event data, es-
pecially time-to-death. However, there is growing evidence
in the literature favoring a different approach that taken
into account a competing risk event, particularly in neph-
rology [21,22]. This is mainly because the dropouts due to
kidney transplant might mislead the interpretation of
results, as these patients are usually healthier than those
patients who are still on dialysis. In our study, due to the
long-term follow-up, the number of patients who received
transplant was similar to the number of patients who died.
Competing risk analysis however, showed that higher Scl,
presence of diabetes and age were independently associ-
ated to mortality, even when the occurrence of kidney
transplant was considered. This statistical method allows
us to confirm our results, reducing the possibility of
misinterpretation while using the classical Kaplan-Meier.
In the current study, a positive correlation between Scl
and calcitonin was found, in accordance with previous ex-
perimental study, where the anabolic effect of PTH was
blunted by calcitonin [10], implicating this hormone as a
negative regulator of bone formation. Curiously, the au-
thors found that calcitonin exerted this effect through the
stimulation of Scl synthesis. Since CKD patients present an
increase in both circulating Scl [7] and calcitonin [23], an
intriguing hypothesis would be that the second could
stimulate Scl production, justifying, at least partially, the el-
evated Scl found in this population. We also found an asso-
ciation of serum Scl and FGF 23, suggesting a mechanistic
link that has yet to be determined. Interestingly, we have re-
cently described that predialysis patients who were treated
with sevelamer presented simultaneously decreases in both
FGF 23 and Scl [24], opening new avenues for additional
exploration.
Figure 1 Cumulative incidence function for Scl levels during follow up. The regression included age, gender, Scl levels stratified in two
categories (high versus low), FGF23 levels and presence of diabetes.
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Importantly, the here descript positive association of
high serum Scl and increased mortality risk contradicts
the previous finding of Viaene and colleagues [9], who
have found a protective effect of Scl. However, there are
some differences between these studies that could explain
these apparent conflicting results. Our patients were ap-
proximately 25 years younger, with a lower percentage of
diabetes and higher survival rate. Moreover, our analysis
was adjusted for the presence of diabetes, the most power-
ful predictor of survival in our cohort. Finally, this differ-
ence could be explained by the different assays that are
commonly employed to measure circulating Scl [25]. The
fact that our population is demographically different from
worldwide ESRD dialysis patients (younger, with low dia-
betes, and potentially with low cardiovascular risk), does
not allow us to impute our results to other populations.
Conclusions
Our study has important strengths, including its long
follow-up and the evaluation of several demographic and
also biochemical variables that certainly could influence
the outcomes. Also, the competing risk analysis empow-
ered the association between Scl and mortality in a sce-
nario of a large number of kidney transplant competing
with the event of interest, death. However, our study also
has some limitations that should be considered when
interpreting results. First, it has been done in a single
center. Second, the population evaluated could not rep-
resent the majority of patients that are currently on dia-
lysis worldwide. In addition, association does not mean
causation. Third, the long storage period might have in-
terfered in the results. Finally, we used an event per vari-
able ratio that may be considered low for regression
[26], which might be associated with overfitting. Never-
theless, considering the high plausibility and the narrow
confidence intervals for the association between Scl and
the outcome of interest, we do not believe that this
could invalidate our findings. Therefore, prospective,
interventional studies are needed to elucidate whether
clinical interventions to modulate serum Scl would be
able to improve these patients survival.
We have demonstrated that high Scl was associated with
CV mortality in a prevalent dialysis population, in a com-
peting analysis approach. Further studies are necessary to
confirm our data.
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